AI Analysis
AI-generated analysis. Always verify with the original filing.
Deepening net losses and accelerated cash burn marked FY2025 as TuHURA advanced its clinical pipeline amid the Kineta acquisition, with management highlighting risks from unproven operating assumptions and ongoing negative cash flows.
Key Takeaways
1Net income was -$30.1M, a -38.6% widening from -$21.7M prior year, reflecting sustained investment in research and development.
2Diluted EPS improved to -$0.63 from -$1.21, a 47.9% less negative result year-over-year due to share dynamics.
3Operating cash flow was -$27.6M versus -$14.7M last year, driven by higher operating expenses including non-cash stock compensation.
4Free cash flow reached -$27.7M after $76K capex, signaling intensified cash usage from core operations.